ReportGem ReportGem

U.S. COMPANY FILING

Moderna, Inc. — Form 8-K filed 2026-01-12

Filed: 2026-01-12Company: Moderna, Inc.Ticker: MRNAExchange: NasdaqForm: 8-KReport period: 2026-01-12SEC accession: 0001682852-26-000007Event: earningsMateriality: 70

Filing text preview

Moderna issued a press release on January 12, 2026, at the 44th Annual J.P. Morgan Healthcare Conference, providing preliminary financial information for fiscal year 2025: expected revenue of approximately $1.9 billion, GAAP operating expenses of $5.0-$5.2 billion, and cash, equivalents, and investments of approximately $8.1 billion. The audit is ongoing and figures may change.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-01-12US Treasury to At Least Double Debt Buybacks; Stock Futures Climb2026-08-20Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-20US Stock Index Futures Climb As Yields Cool Off Amid Treasury Support2026-08-20Wall St Rises as Yields Ease, Moderna Lifts Healthcare Stocks2026-08-20Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data, Personalized Cancer Vaccine Meets Goal2026-08-2010-Q2026-07-31 · 10-Q